martes, 6 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· July 20, 2026

American Fusion Inc. (OTC: AMFN) Receives Texas DSHS Certificate for All 12 Registered Texatron™ Fusion Engine™ Models; Testing Expected the Week of July 27, 2026

View original at globenewswire.com

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The certificate does not certify commercial performance but provides authorization to conduct the covered research program; the next objective is generating credible, reproducible and properly documented technical data.

    60% confidence

  • The DSHS certificate covering all 12 registered Texatron™ models represents one of the most significant operational milestones in the Company's development and moves it closer to obtaining technical data required for future commercialization.

    60% confidence

  • This milestone represents another major step in American Fusion's development, bringing together scientific innovation, regulatory discipline, experienced personnel and a clear testing program.

    60% confidence

  • Excitement about beginning planned Texatron™ testing at Texas Tech, applying advanced scientific instrumentation and disciplined testing procedures to evaluate an innovative compact-fusion platform.

    60% confidence

  • Receiving the certificate for all 12 Texatron™ model classes is an extraordinary achievement enabling a new phase of disciplined experimental evaluation, including re-testing the 500-kilowatt system and beginning work on the 5-megawatt Texatron™.

    60% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com